BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

医学 内科学 队列 肿瘤科 化学免疫疗法 无进展生存期 肺癌 阶段(地层学) 化疗 癌症 免疫疗法 生物 古生物学
作者
Mariano Provencio,Lucía Robado de Lope,Roberto Serna‐Blasco,Ernest Nadal,P. Diz Taín,Bartomeu Massutí,J.L. González-Larriba,Amelia Insa,Alfredo Sánchez-Hernández,Joaquín Casal‐Rubio,Rosario García‐Campelo,Silvia Sequero López,Jacobo Rogado,Alex Martínez‐Martí,Joaquím Bosch-Barrera,Reyes Bernabé,Sergio Vázquez‐Estévez,Santiago Ponce,Javier de Castro,J. Coves Sarto
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:194: 107865-107865 被引量:4
标识
DOI:10.1016/j.lungcan.2024.107865
摘要

BackgroundImmunotherapy-based treatments have demonstrated high efficacy in patients with advanced and locally advanced non-small-cell lung cancer (NSCLC). BRAF mutations affect a small but significant fraction of NSCLC. The efficacy of these therapies in this subgroup of patients is unknown.Materials and methodsPlasma and tissue samples from 116 resectable stage IIIA/B NSCLC patients, included in NADIM and NADIM II clinical trials (NADIM cohort), and from a prospective academic cohort with 84 stage IV NSCLC patients (BLI-O cohort), were analyzed by next-generation sequencing.ResultsThe p.G464E, p.G466R, p.G466V, p.G469V, p.L597Q, p.T599I, p.V600E (n = 2) BRAF mutations, were identified in four (3.45 %) samples from the NADIM cohort, all of which were cases treated with neoadjuvant chemoimmunotherapy (CH-IO), and four (4.76 %) samples from the BLI-O cohort, corresponding to cases treated with first-line immunotherapy (n = 2) or CH-IO (n = 2). All these patients were alive and had no evidence of disease at data cut-off. Conversely, patients with BRAF wild-type (wt) tumors in the BLI-O cohort had a median progression-free survival (PFS) of 5.49 months and a median overall survival (OS) of 12.00 months (P-LogRank = 0.013 and 0.046, respectively). Likewise, PFS and OS probabilities at 36 months were 60.5 % and 76.1 % for patients with BRAF-wt tumors in the NADIM cohort. The pathological complete response (pCR) rate after neoadjuvant CH-IO in patients with BRAF-positive tumors (n = 4) was 100 %, whereas the pCR rate in the BRAF-wt population was 44.3 % (RR: 2.26; 95 % CI: 1.78–2.85; P < 0.001).ConclusionBRAF mutations may be a good prognostic factor for advanced and locally advanced NSCLC patients undergoing immunotherapy-based treatments.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小兔狸花昕完成签到,获得积分20
1秒前
IRer79完成签到,获得积分10
3秒前
彭于晏应助noah采纳,获得10
3秒前
青年才俊发布了新的文献求助10
3秒前
zhu发布了新的文献求助10
4秒前
波波蛋完成签到,获得积分10
4秒前
5秒前
6秒前
7秒前
maguodrgon发布了新的文献求助10
10秒前
科研通AI5应助shell采纳,获得80
10秒前
波波蛋发布了新的文献求助10
10秒前
11秒前
九鹤完成签到,获得积分10
11秒前
jsy完成签到,获得积分10
11秒前
量子星尘发布了新的文献求助10
12秒前
旷野发布了新的文献求助10
12秒前
12秒前
Owen应助浮云521采纳,获得10
12秒前
浮游应助muming采纳,获得10
12秒前
酷炫的凤妖完成签到 ,获得积分10
13秒前
14秒前
14秒前
16秒前
16秒前
16秒前
17秒前
18秒前
浮游应助勤劳的莆采纳,获得10
18秒前
19秒前
霜降发布了新的文献求助10
20秒前
jsy发布了新的文献求助10
20秒前
daring完成签到,获得积分10
20秒前
20秒前
上官若男应助maguodrgon采纳,获得10
22秒前
pomfret发布了新的文献求助10
22秒前
wsx完成签到,获得积分10
23秒前
周学亮关注了科研通微信公众号
24秒前
曾峥发布了新的文献求助10
25秒前
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Zeolites: From Fundamentals to Emerging Applications 1500
Architectural Corrosion and Critical Infrastructure 1000
Early Devonian echinoderms from Victoria (Rhombifera, Blastoidea and Ophiocistioidea) 1000
By R. Scott Kretchmar - Practical Philosophy of Sport and Physical Activity - 2nd (second) Edition: 2nd (second) Edition 666
Energy-Size Reduction Relationships In Comminution 500
Principles Of Comminution, I-Size Distribution And Surface Calculations 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4941339
求助须知:如何正确求助?哪些是违规求助? 4207390
关于积分的说明 13077624
捐赠科研通 3986257
什么是DOI,文献DOI怎么找? 2182529
邀请新用户注册赠送积分活动 1198125
关于科研通互助平台的介绍 1110387